SRG OncoRat is a Sprague-Dawley rat with knockouts for Rag2 and Il2rgamma genes resulting in lack of B-, T-, & NK-cells. Tumor take rates & growth are superior to mouse, consistently increasing study success while reducing animal numbers (i.e. VCaP prostate, H358 NSCLC & PDX models). Tumors grow ~10x larger enabling PDX establishment in a single passage, shortening timelines and providing more translational studies. Below are some examples of how SRG OncoRat outperforms the mouse for xenografts.
Improved engraftment enables oncology research
In mice many xenografts show low, non-existent or inconsistent engraftment efficiency. Engraftment efficiencies in 5-20% range are quite common; making it challenging or impossible to generate a cohort of animals with similar tumor sizes for an efficacy study. The OncoRat has demonstrated improved take rates and kinetics enabling effective in vivo studies using tumor models not previously feasible.
VCaP prostate cancer cells known to have poor engraftment rates and kinetics in immunodeficient mice (i.e. nude mice, SCID mice, NSG mice), thrived in the OncoRat. Preclinical studies with Enzalutamide against the VCaP tumor performed as expected.
Get to efficacy studies & data faster
OncoRat grows ~10x larger tumors and produces larger samples for analysis. As such, patient derived xenograft (PDX) material may be expanded faster, getting to efficacy studies in fewer passages and a shorter amount of time in OncoRat.
The first humanized immune system rat
SRG rats demonstrate robust immune-system humanization with peripheral blood mononuclear cells. Humanized SRG rats may have advantages in immuno-oncology, especially for tumor models with low take-rates in mice.
Human PBMCs were collected and injected into SRG rats for engraftment. By 4 weeks post-transplant, recipients had an average of 29% circulating human CD45+ cells. As of 10 weeks post-transplant, recipients have up to 46% human CD45+ cells and remain healthy.
More precise data and cost savings with efficacy & safety in one animal